Measuring levels of inflammation in patients with heart failure and how they relate to heart function and quality of life

Inflammation and Salt-inducible kinases - a potential novel therapeutic strategy in patients with heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN15573532

Enrollment

100

Registered

2022-07-15

Start date

2022-07-20

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure Circulatory System

Interventions

Blood samples, echocardiography and a quality of life questionnaire will be performed in all patients at baseline. Hospitalised patients will have blood sampling performed at 5 days (or on the day of

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults (>18 years) 2. Diagnosis of heart failure (stage B or stage C) 3. Able to give informed consent

Exclusion criteria

Exclusion criteria: Unable or unwilling to give consent

Design outcomes

Primary

Measure	Time frame
Level of SIK activity measured by blood test at baseline	—

Secondary

Measure	Time frame
At baseline: 1. Other blood markers of inflammation (interleukins 1-beta, 6 and 10, C-reactive protein) 2. Quality of life measured by the Kansas City Cardiomyopathy Questionnaire 3. Left ventricular ejection fraction measured by echocardiography	—

Countries

Scotland, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026